Patent Grant
12168011
The present invention relates to a process for producing a sterile formulation comprising an active pharmaceutical ingredient.
Certain pharmaceutical products must meet stringent sterility standards before they can be administered to patients. In view of the importance of sterility for pharmaceutical products, a large number of different processes, protocols and techniques have been developed for sterilisation of pharmaceutical products. These include steam sterilisation, dry heat sterilisation, ionising radiation sterilisation (including x-ray and gamma-ray sterilisation), gas sterilisation, sterile filtration and aseptic processing. The selection of a sterilisation protocol for a new pharmaceutical product is a complex process which relies on evaluation of the various available methods and their suitability for the specific product.
Ensifentrine (N-(2-{(2E)-9,10-dimethoxy-4-oxo-2-[(2,4,6-trimethylphenyl)imino]-6,7-dihydro-2H-pyrimido[6,1-a]isoquinolin-3(4H)-yl}ethyl)urea; also known as RPL554) is a dual PDE3/PDE4 inhibitor and is described in WO 00/58308 A1. Ensifentrine has both bronchodilatory and anti-inflammatory activity and is useful in the treatment of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD). The structure of ensifentrine is shown below.
Ensifentrine may be formulated as a suspension of particles in a diluent as described in WO 2016/042313 A1.
No suitable method for sterilising a liquid pharmaceutical composition comprising ensifentrine particles has been described. There is a need to develop a process for producing a sterilised ensifentrine suspension.
The inventors have found that, of all the available sterilisation techniques, dry heat sterilization of particles of active agent followed by aseptic compounding is particularly well-suited to formulation of ensifentrine as a suspension. Other techniques such as terminal sterilisation or dry gamma-ray sterilisation were found to cause degradation of the formulations.
The invention accordingly provides a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles, and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation.
The invention further provides a process for producing an ampule comprising a sterile liquid pharmaceutical composition suitable for administration by inhalation, the process comprising: (i) producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles by the process defined herein, and (ii) filling an ampule with the sterile liquid pharmaceutical composition suitable for administration by inhalation.
The process of the invention produces a sterile liquid pharmaceutical composition. The sterile liquid pharmaceutical composition is suitable for administration by inhalation. The sterile liquid pharmaceutical composition comprises sterile ensifentrine particles.
The term “sterile” refers to a composition which is essentially free of viable microbes. As such, a sterile composition is typically a composition which is substantially free of viable bacteria or fungi. The term “sterile” is well known in the art.
The sterile liquid pharmaceutical composition may have a sterility assurance level (SAL) of less than or equal to 10−3, less than or equal to 10−6, or less than or equal to 10−9. For instance, an SAL of 10−6 means that the probability that a final product is non-sterile is 1/106. The sterile liquid pharmaceutical composition may have a total bioburden limit of less than or equal to 10 CFU/mL, or less than or equal to 1 CFU/mL. “CFU” is a colony forming unit. The bioburden may be as measured using a plate count method as described in USP 31<61>, for instance the pour-plate method.
Typically, the sterility of the liquid pharmaceutical composition is as determined in accordance with USP<71> or Ph Eur 2.6.1. The liquid pharmaceutical composition typically meets the acceptance criteria as defined in USP<71> or Ph Eur2.6.1.
The pharmaceutical composition is a liquid pharmaceutical composition and, as such, is liquid under ambient conditions (for instance at temperatures from 10 to 40° C.).
The sterile liquid pharmaceutical composition comprises sterile ensifentrine particles. The ensifentrine particles comprise ensifentrine (i.e. ensifentrine free base) or a pharmaceutically acceptable salt thereof. Typically, the ensifentrine particles comprise ensifentrine free base. The ensifentrine particles typically comprise at least 90.0 wt % of ensifentrine or a pharmaceutically acceptable salt thereof, preferably at least 95.0 wt %. The ensifentrine particles may consist essentially of ensifentrine or a pharmaceutically acceptable salt thereof, or may consist of ensifentrine or a pharmaceutically acceptable salt thereof. For instance, the ensifentrine particles may consist of ensifentrine free base.
A composition which consists essentially of a component comprises only that component and other components which do not materially affect the essential characteristics of the component of which the composition essentially consists. A composition consisting essentially of a component typically comprises at least 99.5 wt % of that component relative to the total weight of the composition.
The sterile ensifentrine particles in the sterile liquid pharmaceutical composition may be suspended in the sterile liquid vehicle. The sterile liquid pharmaceutical composition accordingly typically comprises a suspension of the ensifentrine particles. It may also be the case that some or all of the ensifentrine particles in the sterile liquid pharmaceutical composition have settled to the bottom of a receptacle containing the sterile liquid pharmaceutical composition, for instance after storage for a period of time. The ensifentrine particles may be re-suspended in any suitable way, for instance by agitation of the sterile liquid pharmaceutical composition.
Step (a) of the process typically comprises heating the ensifentrine particles at a temperature of from 120° C. to 200° C. The process may comprise heating the ensifentrine particles at a temperature of from 140° C. to 180° C., for instance from 150° C. to 170° C. or from 155° C. to 165° C.
The ensifentrine particles may be heated for any period of time suitable for producing sterile ensifentrine particles. The process typically comprises heating the ensifentrine particles at the temperature for a time of from 10 minutes to 24 hours. The process may comprise heating the ensifentrine particles at the temperature for a time of from 30 minutes to 360 minutes, for instance from 45 minutes to 160 minutes or from 60 minutes to 140 minutes.
The process preferably comprises heating the ensifentrine particles at a temperature of from 145° C. to 175° C. for a time of from 45 minutes to 160 minutes. For instance, the process may comprise heating the ensifentrine particles at a temperature of from 155° C. to 165° C. for a time of from 110 minutes to 130 minutes.
Heating the ensifentrine particles at a temperature in a certain range for a certain time means that the temperature of the ensifentrine particles is held at a temperature within that range for the total time. The ensifentrine particles are typically heated for the relevant time in a single heating step, but the heating may alternatively be conducted in two or more separate heating steps. For instance, heating at a temperature of from 140° C. to 180° C. for 60 minutes may comprising a single heating step for a duration of 60 minutes or two separate heating steps each having a duration of 30 minutes. Typically the ensifentrine particles are heated in a single heating step at the temperature for the time.
Step (a) is typically a dry heat sterilisation process. The ensifentrine particles are typically in the form of a dry powder. The process accordingly may comprise heating a dry powder comprising ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain a sterile dry powder comprising ensifentrine particles. Typically, the ensifentrine particles are subjected to dry-heat treatment on their own. The process may comprise heating a dry powder of ensifentrine particles (i.e. a dry powder consisting essentially of ensifentrine particles) at a temperature of from 100° C. to 220° C. to obtain a sterile dry powder of ensifentrine particles. A dry powder is typically a powder having a water content of less than 5.0 wt %, less than 1.0 wt % or less than 0.1 wt %.
The ensifentrine particles typically have a particle size distribution with a Dv50 of from 0.5 μm to 5.0 μm. The ensifentrine particles preferably have a Dv50 of from 1.0 μm to 2.0 μm. Typically, the Dv10 of the ensifentrine particles is from 0.2 μm to 1.0 μm and the Dv90 of the ensifentrine particles is from 2.5 μm to 6.0 μm. For instance, the Dv10 of the ensifentrine particles may be from 0.4 μm to 0.6 μm and the Dv90 of the ensifentrine particles may be from 2.8 μm to 4.2 μm.
Particle sizes are described herein by reference to the Dv50 value, which is the median particle size for a volume distribution. Thus, half the volume of the particles have diameters of less than the Dv50 value and half the volume of the particles have diameters of greater than the Dv50 value. This is a well-known manner in which to describe particle size distributions. The parameters of Dv10 and Dv90 may also be used to characterise a particle size distribution of a sample. 10% of the volume of particles have a diameter of less than the Dv10 value. 90% of the volume of the particles have a diameter of less than the Dv90 value.
The technique used to measure the Dv50 (and Dv10 and Dv90) values as stated herein is typically laser diffraction. The particle size distribution of the ensifentrine particles may be as measured by laser diffraction using a wet powder dispersion system. For instance, the particle size distribution can be measured by laser diffraction using a Malvern Spraytec in conjunction with a wet dispersion cell.
Typically, the instrument parameters for the Malvern Spraytec are as follows:
The ensifentrine particles may be produced by any pharmaceutically acceptable size reduction process or particle size controlled production process. For instance, the particles may be produced by spray-drying a solution of ensifentrine, by controlled crystallisation, or by size reduction of a solid form of ensifentrine, for example by air jet milling, mechanical micronisation or media milling.
The process further comprises combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. Combining the sterile ensifentrine particles with a sterile liquid vehicle typically comprises mixing the sterile ensifentrine particles with a sterile liquid vehicle.
The sterile liquid vehicle typically comprises one or more diluents. The diluent may be any suitable liquid diluent. For instance, the sterile liquid vehicle typically comprises a diluent which is water. The sterile liquid vehicle may comprise one or more additional diluents or the sterile liquid vehicle may comprise a single diluent. The sterile liquid vehicle may comprise a single diluent which is water.
A sterile liquid vehicle comprising water may be used to produce a sterile liquid pharmaceutical composition suitable for use in a nebulizer. The sterile liquid vehicle typically further comprises one or more additional excipients selected from surfactants, buffers and tonicity adjusters.
The sterile liquid vehicle typically further comprises a tonicity adjuster. Examples of tonicity adjusters include sodium chloride, potassium chloride, glucose, glycerine and mannitol. Preferably, the tonicity adjuster is sodium chloride.
The concentration of the tonicity adjuster in the sterile liquid vehicle is typically greater than or equal to 1.0 mg/mL (for instance from 1.0 to 50.0 mg/mL). Preferably, the tonicity adjuster concentration is from 4.0 to 20.0 mg/mL or from 6.0 to 12.0 mg/mL.
The sterile liquid vehicle typically further comprises one or more surfactants. The one or more surfactant may comprise a non-ionic surfactant, an anionic surfactant, a cationic surfactant, a zwitterionic surfactant or a mixture thereof. Typically, the one or more surfactants comprise a non-ionic surfactant.
Examples of surfactants include lecithin, oleic acid, polyoxyethylene glycol alkyl ethers (for instance PEG 300, PEG 600, PEG 1000, Brij 30, Brij 35, Brij 56, Brij 76 and Brij 97), polypropylene glycol (for instance PPG 2000), glucoside alkyl ethers, polyoxyethylene glycol octylphenol ethers, polyoxyethylene glycol alkylphenol ethers, glycerol alkyl esters, polyoxyethylene glycol sorbitan alkyl esters (polysorbates, for instance polysorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80), sorbitan alkyl esters (for instance sorbitan monolaurate (Span® 20), sorbitan monooleate (Span® 80) and sorbitan trioleate (Span® 85)), cocamide MEA, cocamide DEA, dodecyldimethylamine oxide, block copolymers of polyethylene glycol and polypropylene glycol (poloxamers), block copolymers of polyethylene glycol and polypropylene oxide (for instance Pluronic surfactants), polyvinyl pyrrolidone K25, polyvinyl alcohol, oligolactic acid, sodium dioctyl sulfosuccinate and polyethoxylated tallow amine (POEA).
Preferably, the one or more surfactants comprise a polysorbate and/or a sorbitan alkyl ester. The one or more surfactants may for instance comprise polysorbate 20 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 40 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate) or polysorbate 80 (polyoxyethylene (20) sorbitan monooleate). The one or more surfactants may for instance comprise sorbitan monolaurate (Span® 20), sorbitan monooleate (Span® 80) or sorbitan trioleate (Span® 85). Preferably, the sterile liquid vehicle comprises polysorbate 20 and/or sorbitan monolaurate (Span® 20).
The sterile liquid vehicle may comprise two or more surfactants, or the sterile liquid vehicle may comprise a single surfactant. For instance the composition may comprise a single surfactant which is a polysorbate, for instance polysorbate 20. The sterile liquid vehicle may comprise two or more surfactants. For instance, the sterile liquid vehicle may comprise polysorbate 20 and sorbitan monolaurate (Span® 20).
The total concentration of the one or more surfactants in the sterile liquid vehicle is typically from 0.01 to 2.0 mg/mL. Preferably, the total surfactant concentration is from 0.1 to 1.0 mg/mL. For instance, the total surfactant concentration in the sterile liquid vehicle may be from 0.25 to 0.75 mg/mL. The sterile liquid vehicle may for instance comprise a polysorbate at a concentration of from 0.1 to 1.0 mg/mL and optionally a sorbitan alkyl ester at a concentration of from 0.01 to 0.1 mg/mL.
The sterile liquid vehicle typically further comprises one or more buffers. The buffer can be used to control the pH of the liquid pharmaceutical composition. A buffer typically comprises a weak acid and its conjugate base. Examples of buffers include a citrate buffer, a phosphate buffer, an acetate buffer, and a bicarbonate buffer.
Preferably, the buffer is a phosphate buffer. For instance, the sterile liquid vehicle may comprise sodium dihydrogen phosphate dihydrate and/or disodium phosphate dihydrate.
The pH of the sterile liquid vehicle is typically from 6.0 to 7.5, for instance from 6.2 to 7.2. The pH of the sterile liquid vehicle may be from 6.5 to 6.9. The pH of the sterile liquid vehicle is typically the pH as measured at a temperature of 20° C. The pH of the sterile liquid vehicle may be measured by any suitable technique. For instance, the pH may be as measured using a potentiometric pH meter.
The total concentration of the one or more buffers in the sterile liquid vehicle is typically from 0.1 to 20.0 mg/mL. Preferably the buffer concentration is from 1.0 to 2.0 mg/mL. The concentration of the buffer includes both the acid and conjugate base components of the buffer.
Typically, the sterile liquid vehicle comprises: water, one or more tonicity adjusters, one or more buffers, and one or more surfactants. The sterile liquid vehicle may for instance comprise: water, sodium chloride, sodium dihydrogen phosphate dihydrate, disodium phosphate dihydrate, polysorbate 20 and sorbitan laurate.
The process typically further comprises producing the sterile liquid vehicle. The sterile liquid vehicle may be produced by sterilising a liquid vehicle, for instance by aseptic filtration, heat treatment or gamma-ray treatment of a liquid vehicle. The sterile liquid vehicle is typically produced by aseptic filtration of a liquid vehicle. Aseptic filtration typically comprises filtering a liquid vehicle through a filter having a nominal pore size of no greater than 0.5 μm, or no greater than 0.3 μm (for instance around 0.2 μm).
The process of the invention produces a sterile liquid pharmaceutical composition through aseptic processing and compounding. As such, the process typically does not further comprise an additional step of terminal sterilisation (which has been found to cause the presence of impurities in the composition). For instance, the process typically does not further comprise heating the sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles at a temperature of 100° C. or greater.
The concentration of ensifentrine particles in the sterile liquid pharmaceutical composition produced by the process can be any suitable concentration, for instance from 0.01 to 400 mg/mL. Typically, the concentration of ensifentrine particles is from 0.1 to 5.0 mg/mL. Preferably, the concentration of ensifentrine particles is from 0.1 to 2.5 mg/mL. For instance, the concentration of ensifentrine particles may be from 0.15 to 0.5 mg/mL or from 1.0 to 2.0 mg/mL.
For instance, the sterile liquid pharmaceutical composition may comprise:
The sterile liquid pharmaceutical composition may comprise:
The invention also provides a process for producing an ampule comprising a sterile liquid pharmaceutical composition suitable for administration by inhalation. The process comprises: (i) producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles by a process as defined herein; and (ii) filling an ampule with the sterile liquid pharmaceutical composition suitable for administration by inhalation. The ampule may be a glass ampule or a plastic ampule. The ampule is typically a polyethylene plastic ampule. The ampule may be individually overwrapped in an aluminium foil pouch after filling.
The ampule may be a blow-fill-seal ampule. For instance, the process may be a process for producing an ampule using blow-fill-seal technology, which ampule comprises a sterile liquid pharmaceutical composition suitable for administration by inhalation, the process comprising: (i) producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles by the process defined herein; and (ii) producing a blow-fill-seal ampule filled with the sterile liquid pharmaceutical composition suitable for administration by inhalation.
Assay testing was performed in duplicate with the key high performance liquid chromatography (HPLC) parameters shown in Table 1.
Impurities determination was performed in duplicate with the key high performance liquid chromatography (HPLC) parameters shown in Table 2.
The effect of different sterilisation techniques were assessed on:
Three aqueous suspensions having the formulations shown in Tables 3 to 5 were prepared.
The unformulated ensifentrine particles were assessed as a dry powder.
Sterilisation Techniques
The sterilisation techniques shown in Table 6 were assessed.
The sterilised micronised ensifentrine obtained from techniques C to F may be subsequently combined with an aseptic vehicle to obtain a suspension formulation.
The assays and related substances of the products obtained by each of sterilisation techniques A to F were assessed by the HPLC methods described above. The results are summarised in Table 7.
The results in Table 7 indicated that terminal heat treatment (technique A), terminal gamma irradiation (technique B) and dry gamma irradiation (technique F) caused some degradation when used for preparation of a sterilised suspension of ensifentrine particles.
It was found, however, that ensifentrine particles were highly resistant to sterilisation by dry heat treatment, with no significant changes in purity or assay following treatment at temperatures of from 150° C. to 170° C. Dry heat treatment at 160° C. for at least 120 minutes is preferred. The sterilised ensifentrine particles obtained by dry heat treatment can be combined with the suspension vehicle in aseptic compounding and processing to obtain a sterile suspension formulation comprising ensifentrine.
| Number | Date | Country | Kind |
|---|---|---|---|
| 2202297 | Feb 2022 | GB | national |
This application is a continuation of International Patent Application No. PCT/GB2023/050372, filed Feb. 20, 2023, which claims the benefit of GB Application No. 2202297.4, filed Feb. 21, 2022, each of which is incorporated herein by reference in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4482556 | Lal et al. | Nov 1984 | A |
| 5378818 | Mayer et al. | Jan 1995 | A |
| 5985878 | Stokbroekx et al. | Nov 1999 | A |
| 6794391 | Oxford et al. | Sep 2004 | B2 |
| 7105663 | Oxford et al. | Sep 2006 | B2 |
| 7378424 | Oxford et al. | May 2008 | B2 |
| 8221772 | Johnson et al. | Jul 2012 | B2 |
| 8242127 | Oxford et al. | Aug 2012 | B2 |
| 9062047 | Walker et al. | Jun 2015 | B2 |
| 9700558 | Walker et al. | Jul 2017 | B2 |
| 9717732 | Walker et al. | Aug 2017 | B2 |
| 9956171 | Spargo et al. | May 2018 | B2 |
| 10463665 | Spargo et al. | Nov 2019 | B2 |
| 10471063 | Walker et al. | Nov 2019 | B2 |
| 10710998 | Spargo | Jul 2020 | B2 |
| 10864213 | Abbott-Banner et al. | Dec 2020 | B2 |
| 10945950 | Spargo et al. | Mar 2021 | B2 |
| 11491155 | Spargo et al. | Nov 2022 | B2 |
| 11759467 | Abbott-Banner et al. | Sep 2023 | B2 |
| 20030036542 | Oxford et al. | Feb 2003 | A1 |
| 20030229108 | De Belin et al. | Dec 2003 | A1 |
| 20040076668 | Berchielli et al. | Apr 2004 | A1 |
| 20040171828 | Oxford et al. | Sep 2004 | A1 |
| 20040176353 | Oxford et al. | Sep 2004 | A1 |
| 20040247628 | Lintz et al. | Dec 2004 | A1 |
| 20050054655 | Beaulieu et al. | Mar 2005 | A1 |
| 20050186276 | Berchielli et al. | Aug 2005 | A1 |
| 20050261271 | Feng et al. | Nov 2005 | A1 |
| 20070197489 | Karlsson | Aug 2007 | A1 |
| 20080003283 | Feng et al. | Jan 2008 | A1 |
| 20080108807 | Feng et al. | May 2008 | A1 |
| 20080108808 | Feng et al. | May 2008 | A1 |
| 20080113993 | De Belin et al. | May 2008 | A1 |
| 20080125437 | Dong et al. | May 2008 | A1 |
| 20080142759 | Pays | Jun 2008 | A1 |
| 20080161562 | Feng et al. | Jul 2008 | A1 |
| 20080177064 | Feng et al. | Jul 2008 | A1 |
| 20080188501 | Feng et al. | Aug 2008 | A1 |
| 20080199410 | Johnson et al. | Aug 2008 | A1 |
| 20080206163 | Oxford et al. | Aug 2008 | A1 |
| 20090012059 | Feng et al. | Jan 2009 | A1 |
| 20090075939 | He et al. | Mar 2009 | A1 |
| 20100113413 | Dong et al. | May 2010 | A1 |
| 20100204471 | Dong et al. | Aug 2010 | A1 |
| 20110076276 | Guo et al. | Mar 2011 | A1 |
| 20110190261 | Dong et al. | Aug 2011 | A1 |
| 20120251594 | Longest et al. | Oct 2012 | A1 |
| 20120302533 | Oxford et al. | Nov 2012 | A1 |
| 20130078256 | Guo et al. | Mar 2013 | A1 |
| 20130158021 | Dong et al. | Jun 2013 | A1 |
| 20130225616 | Walker et al. | Aug 2013 | A1 |
| 20160000790 | Walker et al. | Jan 2016 | A1 |
| 20160008363 | Walker et al. | Jan 2016 | A1 |
| 20170112839 | Abbott-Banner et al. | Apr 2017 | A1 |
| 20170239178 | Spargo et al. | Aug 2017 | A1 |
| 20170266190 | Walker et al. | Sep 2017 | A1 |
| 20180021337 | Spargo et al. | Jan 2018 | A1 |
| 20180369139 | Spargo et al. | Dec 2018 | A1 |
| 20190330206 | Spargo | Oct 2019 | A1 |
| 20200016158 | Spargo et al. | Jan 2020 | A1 |
| 20210106585 | Abbott-Banner et al. | Apr 2021 | A1 |
| 20210379053 | Spargo et al. | Dec 2021 | A1 |
| 20220265549 | Spargo et al. | Aug 2022 | A1 |
| 20230112220 | Spargo et al. | Apr 2023 | A1 |
| Number | Date | Country |
|---|---|---|
| 527997 | Mar 1983 | AU |
| 2847693 | May 1980 | DE |
| 4240981 | Jun 1994 | DE |
| 19612194 | Oct 1997 | DE |
| 19820947 | Nov 1998 | DE |
| 19821263 | Nov 1998 | DE |
| 19726241 | Dec 1998 | DE |
| 0601401 | Jun 1994 | EP |
| 0876366 | Nov 1998 | EP |
| 0983334 | Mar 2000 | EP |
| 1305026 | May 2003 | EP |
| 1418896 | May 2004 | EP |
| 1438019 | Jul 2004 | EP |
| 1519711 | Apr 2005 | EP |
| 1586571 | Oct 2005 | EP |
| 1651611 | May 2006 | EP |
| 1825467 | Aug 2007 | EP |
| 1892269 | Feb 2008 | EP |
| 1993540 | Nov 2008 | EP |
| 2063903 | Jun 2009 | EP |
| 2167476 | Mar 2010 | EP |
| 2001213867 | Aug 2001 | JP |
| 3675274 | Jul 2005 | JP |
| 2005263780 | Sep 2005 | JP |
| 101361145 | Feb 2014 | KR |
| WO-9726258 | Jul 1997 | WO |
| WO-9736039 | Oct 1997 | WO |
| WO-9845293 | Oct 1998 | WO |
| WO-9851772 | Nov 1998 | WO |
| WO-9901607 | Jan 1999 | WO |
| WO-0058308 | Oct 2000 | WO |
| WO-0058309 | Oct 2000 | WO |
| WO-0193841 | Dec 2001 | WO |
| WO-03000343 | Jan 2003 | WO |
| WO-03035030 | May 2003 | WO |
| WO-03037262 | May 2003 | WO |
| WO-2004004684 | Jan 2004 | WO |
| WO-2005007092 | Jan 2005 | WO |
| WO-2005007138 | Jan 2005 | WO |
| WO-2005021510 | Mar 2005 | WO |
| WO-2005095381 | Oct 2005 | WO |
| WO-2006061398 | Jun 2006 | WO |
| WO-2008023249 | Feb 2008 | WO |
| WO-2008036293 | Mar 2008 | WO |
| WO-2008140553 | Nov 2008 | WO |
| WO-2009005674 | Jan 2009 | WO |
| WO-2012020016 | Feb 2012 | WO |
| WO-2012037782 | Mar 2012 | WO |
| WO-2012051426 | Apr 2012 | WO |
| WO-2013063468 | May 2013 | WO |
| WO-2013092791 | Jun 2013 | WO |
| WO-2013118855 | Aug 2013 | WO |
| WO-2013128283 | Sep 2013 | WO |
| WO-2014140647 | Sep 2014 | WO |
| WO-2014140648 | Sep 2014 | WO |
| WO-2015173551 | Nov 2015 | WO |
| WO-2016042313 | Mar 2016 | WO |
| WO-2016128742 | Aug 2016 | WO |
| WO-2018020249 | Feb 2018 | WO |
| WO-2020074894 | Apr 2020 | WO |
| WO-2021028679 | Feb 2021 | WO |
| WO-2021171034 | Sep 2021 | WO |
| Entry |
|---|
| SPAN 20 (sorbitan monolaurate product page) (Year: 2024). |
| TWEEN 20 (polyoxyethylene sorbitan monolaurate product page) (Year: 2024). |
| Akers (Sterile Drug Products: Formulation, Packaging, Manufacture and Quality. Published 2010) (Year: 2010). |
| Bjermer, L. et al., Efficacy and safety of a first-in-class inhaled PDE3/4 inhibitor (ensifentrine) vs salbutamol in asthma, Pulmonary Pharmacology & Therapeutics, vol. 58, (2019). |
| Blasko, G. et al., Pyrimido[1,6-a]pyrido[3,4-b]indoles as new platelet inhibiting agents, European Journal of Medicinal Chemistry, vol. 21, 2 (1986):91-5. |
| Chen, E.H. et al., Modifications of primaquine as antimalarials. 1. 5-Phenoxy derivatives of primaquine, Journal of Medicinal Chemistry, vol. 20, 8 (1977):1107-9. |
| Dong-Sheng, M. et al., Synthesis of Daimuron, College of Chemistry and Chemical Engineering, Huaxue Yu Nianhe, vol. 6, (2003):293-295. |
| Franciosi, L.G. et al., Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials, The Lancet. Respiratory Medicine, vol. 1, 9(2013):714-727. |
| Frank, A.W., Synthesis of some carbonyl derivatives of tris(aminomethyl)phosphine oxide, Phosphorus and Sulfur and the Related Elements, vol. 22, 3(1985):265-76. |
| Houlihan, W.J. et al., Synthesis and proton-NMR spectra, Journal of Heterocyclic Chemistry, vol. 19, 6(1982):1453-6. |
| Jansen, M., Derivatives of some nuclear methoxylated B-phenylethylamines, vol. 50, (1931):617-37. |
| Kienzle, F. et al., Synthesis of 6,7-dihydro-2H-pyrimido[6, 1-a]isoquinolin-4(3H)-ones and analogous compounds and their activity as blood platelet aggregation inhibitors, Helvetica Chimica Acta, vol. 69, 7(1986): 1671-80. |
| Kijima, I, et al., Synthesis and reactivities of triisocyanatoantimony, Japan, Nippon Kagaku Kaishi, vol. 12, (1986):1754-57. |
| Lai, B. et al., Synthesis of 2-substituted-6,7-dihydro-4H-pyrimido[6,1-a]thieno[2,3-c]- and [3,2-c]pyridin-4-ones, Heterocycles, vol. 24, 7(1986):1977-85. |
| Lal, B. et al., Trequinsin, a potent new antihypertensive vasodilator in the series of 2-(arylimino)-3-alkyl-9,10-dimethoxy-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-ones, Journal of Medicinal Chemistry, vol. 27, 11(1984):1470-80. |
| Mannich, C. et al., Berichte der Deutschen Chemischen Gesellschaft, vol. 43, (1910):189-97. |
| No Author, European Medicines Agency, Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container, Apr. 11, 2016. |
| No Author, European Medicines Agency, Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container, Mar. 6, 2019. |
| Pai, N.R. et al., Synthesis of novel analogs 3,4-dihydro-1H-quinolin-2-one derivatives as typical Antidepressant, Sedative and anti-Parkinson agents, Heterocyclic Letters, vol. 2, 1 (2012):117-128. |
| Pfleiderer, V.W. et al., Synthesis of 9-substituted xanthines, Justus Liebigs Annalen der Chemie, vol. 631, (1960):168-74. |
| Ratel, M. et al., Imidazolium-Based lonic Liquid Surfaces for Biosensing, Analytical Chemistry, vol. 85, 12 (2013):5770-5777. |
| Tran, P. et al., Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methy-1H-imidazol-1-yl)propyl thiourea template, Bioorganic & Medicinal Chemistry, vol. 21, 13 (2013):3821-3830. |
| USP 1229.8 Dry Heat Sterilization 2018. |
| Number | Date | Country | |
|---|---|---|---|
| 20240165117 A1 | May 2024 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/GB2023/050372 | Feb 2023 | WO |
| Child | 18422922 | US |
